Compound ID | 2779
Synonym(s): Celiomycin | florimycin | tuberactinomycin B | viocin
Class: Natural product antibiotic
| Agent Type: | Natural product; Small molecule; Direct acting; |
| Spectrum of activity: | Antimycobacterial |
| Mechanism of action: | Protein synthesis inhibitor. Blocks elongation factor G-mediated translocation of mRNA |
| Target Pathogen: | Active against Mycobacterium tuberculosis. Mycobacterium ranae, Mycobacterium phlei, and Mycobacterium smegmatis |
| Description: | Natural product from Streptomyces puniceus; administered via injection; used as second line anti-tubercular drug; a tuberactinomycin-type antibiotic |
| Institute where first reported: | Research Laboratories of Parke, Davis & Company, Detroit Michigan USA; Research Laboratories, Chas. Pfizer & Co., Inc., Brooklyn, New York, USA |
| Year first mentioned: | 1951 |
| Highest development stage: | Approved in 1953 |
| Development status: | Discontinued |
| Reason dropped: | Availability of safer alternatives; more effective antibiotic alternatives available |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/135398671 |
| Guide to Pharmacology: | viomycin |
| Citations: |
|